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Plasma aldosterone concentrations in chronic renal disease. The dis-
agreement in the literature concerning the role of aldosterone in the
maintenance of potassium homeostasis in chronic renal disease might
be partially explained by differences in plasma renin activity (PRA)
among individual patients. Therefore, a study was done in 28 selected
patients with varying degrees of renal insufficiency whose serum
potassium and PRA concentrations were within the normal range. The
results indicate that at comparable serum potassium and PRA concen-
trations, plasma aldosterone is in most instances elevated when creati-
nine clearance is lower than 50% of normal.
Concentrations plasmatiques d'aldostérone au cours de l'insuffisance
rénale chronique. Les désaccords de Ia littérature au sujet du role de
l'aldostérone dans le maintien de I'homéostasie du potassium dans
l'insuffisance rénale chronique peuvent étre partiellement expliqués par
les differences entre individus en cc qui concerne l'activité rénine
plasmatique (PRA). Par consequent une étude a été réalisée chez 28
malades sélectionnés ayant des degres divers d'insuffisance rénale et
dont les concentrations de potassium sCrique et les niveaux de PRA
étaient dans l'éventail des valeurs normales. Les résultats indiquent
que, a concentration de potassium sérique et PRA semblables, l'aldos-
terone plasmatique est dans Ia plupart des cas élevée quand Ia clairance
de Ia créatinine est inférieure a 50% des valeurs normales.
Despite progressive loss of functioning nephrons, patients
with chronic renal insufficiency usually show a serum potassi-
um concentration that is within normal limits, even up to a far-
advanced stage of illness. When function decreases, the kid-
neys continue to excrete the same amount of potassium,
because the kidney is able to elevate the fractional excretion. If
it is true that all of the filtered potassium is reabsorbed in the
proximal tubule, then the increased excretion must be the result
of increased tubular secretion [1]. Only in far-advanced renal
insufficiency does increased potassium excretion by the gut
contribute appreciably to total potassium homeostasis [2, 31.
Experimental work in rats has suggested that aldosterone is not
the most important factor in this adaptive process of the kidney,
although the presence of aldosterone is essential in the rat, as
well as in man [4]. In chronic renal disease, normal aldosterone
excretion and plasma concentrations have been reported, which
supports the conclusion that there is "no evidence that in-
creased aldosterone secretion is part of the adaption required to
maintain potassium homeostasis" [4, 5]. In a recent study [6],
markedly increased plasma aldosterone concentrations were
found, but only in patients with creatinine clearances below 12
mi/mm. Because aldosterone secretion is also under the regula-
tory influence of the sodium balance via the renin-angiotensin
system, abnormalities can only be detected if this factor is also
taken into account. The present study shows that, when potas-
sium intake and plasma renin activity are within the normal
range, plasma aldosterone concentrations are increased in
proportion to the degree of renal failure.
Methods
Twenty-eight patients were selected from a group of 39 with
various degrees of renal failure on the basis of normal serum
potassium (4.0 to 5.0 mmoles/liter) and plasma renin activity
(PRA) (200 to 700 fmoles/liter/sec). The patients did not use any
medication except sodium bicarbonate, aluminum hydroxide,
calcium carbonate, and vitamin D supplements. The diagnoses
are listed in Table 1. The patients were assigned to three groups
according to the degree of renal failure; that is, group 2 had
creatinine clearances between 21 and 70 mI/mm; group 3,
between 11 and 20 mI/mm; and group 4, between 3 and 10
mI/mm. Twenty-two healthy volunteers serving as controls
(group 1) were kept on normal diet. Blood samples were
collected at 9 A.M. after the subjects had been in the upright
position for at least half an hour. Twenty-four-hour urine for
analysis was collected during the day before investigation.
Potassium and sodium were measured by flame photometry.
Renal function was assessed by calculating the 24-hour creati-
nine clearance. PRA (fmoles/liter/sec) was determined radioim-
munologically according to a modification of the method de-
scribed by Haber (incubation of undiluted plasma for 1 hr at
37° C and at a pH of 5.6, followed by deproteinization of the
plasma with 4 N ammonia/acetone (1:9) [7]. After 2.0 ml of
plasma was extracted with dichloromethane and purified on
Sephadex LH 20 columns (1.0 >< 50 cm), plasma aldosterone
(PALDO, pmoles/liter) was assayed by radioimmunoassay with
the radioassay buffer as the mobile phase, as described by
Nowaczynski et al [8].
For statistical evaluation, analysis of variance and Student's
test were used. For correlations, Spearman's ranking test was
used.
Results
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The mean values for the four groups are listed in Table 2.
There were no differences in serum potassium concentrations.
The urine potassium excretion was slightly higher in the con-
trols than it was in the patients, due to the difference in diet.
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Table 1. Diagnosis in the three groups of patients with renal failure
Diagnosis Group 2 Group 3 Group 4 Total
Polycystic disease 4 2 3 9
Interstitial nephritis 3 3 4 10
Medullary cystic disease I
Glomerulonephritis 7 3 4 8
Total 14 8 II 28
Urinary potassium was lower in group 4 than it was in groups 2
and 3. This difference may at least partly be due to an increased
potassium excretion by the gut and probably also reflects a
lower potassium intake. Sodium excretion was slightly lower in
group 4. Mean PRA was somewhat low in groups 3 and 4, but
within the limits set by the range of our normal control group.
Mean PALDO was higher than normal in all patients with
decreased renal function and strikingly elevated in group 4,
even in the presence of a slightly reduced urinary potassium
load. Statistical differences (P < 0.01) were found between both
the log PALDO values and the log PALD0/log PRA ratio for
group I vs. groups 2, 3, and 4, group 2 vs. 4, and group 3 vs. 4.
Only the values of groups 2 and 3 did not differ significantly.
Figure 1 gives the individual values for log PALD0/log PRA,
plotted against the creatinine clearance, illustrating that below
creatinine clearances of 50 mI/mm log PALD0/log PRA is
elevated in most instances proportionally to the degree of renal
failure (r = 0.54, P < 0.007). Figure 1 also shows that not all
patients with severe renal insufficiency had an elevated PALDO.
The two patients in group 4 with the lowest log PALD0/log PRA
ratio both suffered from glomerulonephritis, but the other
patients with this disease had elevated values.
Discussion
The role of aldosterone in patients with renal insufficiency
was formerly assessed from the aldosterone secretion or excre-
tion rate. Urine aldosterone determinations may have some
value in patients with moderate renal insufficiency [11, but when
aldosterone clearance is depressed in severe renal failure these
methods will not reflect circulating plasma concentrations [6,
10]. Plasma concentrations are therefore indispensable if the
role of aldosterone is to be evaluated.
Because aldosterone secretion is strongly influenced by PRA,
the role of aldosterone can only be evaluated properly if this
factor is taken into account. Weidmann et a! [11] reported
normal values for PRA and .PALDO in patients with creatinine
clearances ranging from 9.5 to 55.8 mI/mm and a normal serum
potassium concentration. Closer inspection of their data shows,
however, that PRA was low normal and PALDO was in the high
normal range, which means that the PALD0/PRA ratio was
elevated. Berl et a! [6] found a high PALDO in patients with
creatinine clearances below 11 mI/mm and normal serum potas-
sium. Their series comprises only two patients within the
moderately impaired range (creatinine clearance, 25 and 33
mI/mm) who had a normal PALDO. Reubi, Weidmann, and
GlUck [12] recently reported an inverse relationship between
PALDO and the GFR, but their group of patients showed a wide
range of PRA values.
Most patients in our study, who were selected on the basis of
normal PRA and serum potassium concentrations, had in-
creased PALDO concentrations, even in half of group 2 whose
renal function was only moderately decreased. More severe
degrees of renal failure were accompanied by a progressive rise
in PALDO and log PALD0/log PRA ratio (Fig. 1). That this
phenomenon has not been observed previously, except in
patients with far advanced renal disease, is explained by the
interference of PRA levels.
Because we found an elevated plasma aldosterone concentra-
tion in patients with renal insufficiency whose PRA and serum
potassium were normal, it seems likely that aldosterone is
involved in the maintenance of a normal serum potassium level
by increased fractional excretion. Although low aldosterone
concentrations do not usually lead to hyperkalemia in subjects
with normal renal function, the necessity for the presence of
this hormone in chronic renal failure in man is illustrated by the
well-documented syndrome of hyporeninemic hypoaldosteron-
ism [1, 13].
The role of aldosterone in the adaptation of potassium
metabolism in renal insufficiency is still not clear, however. In
the adrenalectomized rat this adaptive process remains intact,
only if a physiologic amount of aldosterone is provided [4].
Among patients with renal disease, at least four different
patterns may be found: patients with normal serum potassium,
with and without increased PALD0, patients in whom both
serum potassium and PALDO are elevated, and patients without
increased PALDO despite elevated serum potassium. As illus-
trated in Fig. 1, two of our patients with severe renal failure and
normal PRA and serum potassium did not show an elevated
PALDO. On the other hand, some patients with advanced renal
failure may show an inability of the kidney to increase the
potassium excretion, despite adequate levels of endogenous or
exogenous mineralocorticoids [14, 151. We observed a hyperka-
lemic patient with normal PRA (440 fmoles/liter/sec) and a very
high PALDO level (6000 pmoles/liter), in whom infusion of
aldosterone had no additional effect on potassium excretion
(unpublished observation). Thus, in our group of patients with
renal failure and normal serum potassium, PALDO tended to be
elevated, although exceptions were noticed.
An explanation of these differences may be the renal tubular
function in relation to the decrease of GFR. The more the
tubular function is affected, the higher PALDO may be required
to make the tubule excrete the desired amount of potassium.
Because 21 of the 28 patients in the present study suffered from
tubulointerstitial diseases, the results may not be applicable to
all types of chronic renal disease, although the 7 patients with
glomerulonephritis as a group could not be clearly distinguished
from the rest.
It is not clear how a decreased renal function induces
increased PALDO levels. Because more than 80% of aldosterone
is metabolized in the liver, renal function does not influence
PALDO by way of the metabolic clearance rate. In acute
potassium-loading experiments in normal subjects, a serum
potassium and PALDO elevation have been found [17]. In
chronic-loading studies, PALDO elevations have only been
found when dietary potassium was increased to at least 200
mmoles/day [18]. In this latter study, marked increases in renal
potassium excretion were present with no detectable change in
plasma potassium. It is therefore not unexpected that in slowly
progressive renal failure adaptation takes place without detect-
able changes in plasma potassium levels.
Conclusion. In our group of patients with renal failure
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Table 2. Biochemical data of the controls (group 1) and the patients with renal failure (groups 24)a
Group N Male Female Age CCR
mi/mm
Serum K
mEqiliter
Urinary K Urinary Na
rnEq/24 hr
Log PRA Log PALDO Log PA!
Log PRA
1 22 15 7 29 8 78—160 4.3 (3.9—4.9) 80 26 166 47 2.70 0.15 (2.32—2.88) 2.67 0.21 1.00 0.05
2 9 5 4 38 8 21—70 4.3 (4.0—4.8) 58 20 101 53 2.70 0.10 (2.56—2.88) 2.95 0.22 1.09 0.09
3 8 6 2 40 II 11—20 4.3 (4.0—4.8) 51 17 139 SI 2.55 0.18 (2.30—2.69) 3.01 0.27 1.17 0.07
4 11 6 5 41 14 3—10 4.4 (3.9—4.9) 32 16 95 54 2.60 0.04 (2.38—2.85) 3.32 0.37 1.27 0.13
Values with sign are means SEM. Parentheses contain the range. PRA was measured in fmoles/liter/sec; and PALDO, in pmoles/liter in
upright position.
Patients
Group Group Group
4 3 2
1.27 1.17 1.09
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Creatinine clearance, mi/rn/n
predominantly but not exclusively due to interstitial diseases,
but with normal serum potassium and normal PRA, an elevated
plasma aldosterone concentration is found, not only in severe,
but also in moderate renal failure.
Acknowledgments
This study was supported by the Dutch Kidney Foundation. Dr. Jan
C. Roos gave advice, and Jan W. van Setten gave technical assistance.
Reprint requests to Dr. R. J. Hené, Department of Nephrology and
Hypertension, University Hospital, Catharijnesingel 101, 3511 GV
Utrecht, The Netherlands
References
1. SCHAMBELAN M, SEBASTIAN A, BIGLIERI EG: Prevalence, patho-
genesis, and functional significance of aldosterone deficiency in
hyperkalemic patients with chronic renal insufficiency. Kidney mt
17:89—101, 1980
2. HAYES CP, MCLEOD ME, ROBINSON RR: An extrarenal mecha-
nism for the maintenance of potassium balance in severe chronic
renal failure. Trans Assoc Am Physicians 80:207—216, 1977
3. BASTL C, HAYSLETT JP, BINDER Hi: Increased large intestinal
secretion of potassium in renal insufficiency. Kidney lot 12:9—16,
1977
4. EPSTEIN FH, CHARNEY AN, SILVA P: Factors influencing the
increase in Na-K-ATPase in compensatory renal hypertrophy, in
Renal Adaptation to Nephron Loss, edited by PETERS G, DIEzI J,
GUIGNARD JP. Basel, S. Karger, 1980, pp. 116—130
5. VAN YPERSELE DE STRIHOU C: Potassium homeostasis in renal
failure. Kidney mt 11:491—504, 1977
6. BERL T, KATZ FH, HENRICH WL, TORRENTE DE A, SCHRIER RW:
Role of aldosterone in the control of sodium excretion in patients
with advanced chronic renal failure. Kidney lot 14:228—235, 1978
7. HABER E, KOERNER T, PAGE LB, KLIMAN B, PURNODE A:
Application of a radioimmunoassay for angiotensin Ito the physio-
logic measurement of plasma renin activity in normal human
subjects. J Gun Endocrinol 29:1349—1355, 1969
8. NOWACZYNSKI W, SASAKI C, GENEST i: Radioimmunoassay for
aldosterone and normal values under various physiological condi-
tions. J Steroid Biochem 5:123—131, 1974
9. COPE CL, PEARSON I: Aldosterone secretion in severe renal failure.
Cliii Sci 25:331—341, 1963
10. BOER P. THIJSSEN JHH: The excretion of metabolites of cortisol
and aldosterone in male patients on haemodialysis treatment.
Steroids 30:203—212, 1977
11. WEIDMAN P, MAXWELL MH, RowE F, WINER R, MASSRY SG:
Role of the renin-angiotensin-aldosterone system in the regulation
Controls (group 1)
1.0
0.05
0
..
1 .4
1.2
C-
1.0-
__ __
0.81
20 40 60 80 100 120 140 160
S 00 0
I I I I—
Fig. 1. Relation between log PALD0/log
PRA and creatinine clearance. For the
patient group, r = 0.54 (P < 0.007).
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